Myriad Genetics falls after preliminary Q4 revenue misses estimates

Myriad Genetics

15/01/2025 15:00

** Shares of medical test kit maker Myriad Genetics  MYGN.O 
fall ~3% to $13.27
    ** MYGN says it expects Q4 rev. to be between $209 mln and
$211 mln, below analyst estimates of $212.9 mln - data compiled
by LSEG
    ** Co expects Q4 adj. EPS to be between 3 cents and 4 cents
vs. analyst est. of 3 cents
    ** Co forecasts 2025 rev. to be between $840 mln and $860
mln below analyst est. of $876.7 mln
    ** Co forecasts 2025 adj. EPS to be between 7 cents and 11
cents vs. analyst est. of 8 cents
    ** 6 of 16 brokerages rate the stock "buy" or higher, 6
"hold" and 4 "sell" or lower; their median PT is $20.50 - LSEG
    ** MYGN fell 27.5% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))